Sandbox/Afib: Difference between revisions
< Sandbox
No edit summary |
No edit summary |
||
Line 107: | Line 107: | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | }} | ||
{{Family tree/end}} | {{Family tree/end}} | ||
{| style="background: #FFFFFF;" | |||
| valign=top | | |||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 600px;" | |||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center; colspan="3"| {{fontcolor|#FFF|CHA2DS2-VASc}} | |||
|- | |||
| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Variable'''|| style="padding: 0 5px; font-size: 100%; background: #F5F5F5;" align=center | '''Score''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Age ≥75 years''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Age 65-74 years''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Female sex''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Diabetes mellitus''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Hypertension''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Congestive heart failure''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Stroke/TIA/Thromboembolism''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''2''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''Vascular disease (prior MI, PAD, or aortic plaque)''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''1''''' | |||
|- | |||
|- | |||
|} | |||
|} | |||
==Do's & Dont's== | ==Do's & Dont's== |
Revision as of 16:19, 1 May 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
New onset atrial fibrillation:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Stable: | Unstable: | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient require heart rate control therapy? | |||||||||||||||||||||||||||||||||||||||||||||||||||||
No | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Identify the underlying etiology and treat accordingly ❑ Proceed with cardioversion & anticoagulation strategy as shown below | Does the patient have any evidence of an accessory pathway (pre-exitation syndrome) | Does the patient has any symptoms and signs of pulmonary edema? ❑ Chest X-ray showing pulmonary edema | |||||||||||||||||||||||||||||||||||||||||||||||||||
No | Yes | Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient has any evidence of heart failure with reduced EF | ❑ IV procainamide or ibutilide ❑ Catheter ablation if the accessory pathway has a short refractory period that allows rapid antegrade conduction | Manage pulmonary edema: ❑ Initiate oxygen therapy
| Immediate DC cardioversion | ||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | After initial pulmonary edema management proceed with DC cardioversion | |||||||||||||||||||||||||||||||||||||||||||||||||||
Heart rate control: ❑ Digoxin | Heart rate control: ❑ Beta blockers or CCB's | Successful | Unsuccessful | ||||||||||||||||||||||||||||||||||||||||||||||||||
Does the patient respond or the arrhythmia terminate (sinus rhythm)? | Identify the underfying cause and treat accordingly | Repeated attempts may be made after adjusting the location of the electrodes or applying pressure over the electrodes, or following administration of an antiarrhythmic medication | |||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Identify the other underlying etiologies and treat accordingly | Oral vs intravenous amiodarone according to the clinical urgency | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Proceed with the anticoagulation strategy as shown below | Does the patient respond or the arrhythmia terminate (sinus rhythm)? | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Identify the underlying etiology and treat accordingly ❑ Proceed with anticoagulation strategy as shown below | Proceed with the cardioversion strategy as shown below | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Cardioversion Strategy
Does the patient with new onset AF has any contraindication for cardioversion : | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
No | Yes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assess stroke risk to initiate long term anticoagulation | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ <48 hours | ❑ >48 hours ❑ Unknown ❑ Prior history of a thromboembolic event ❑ Prior history of TEE evidence of left atrial thrombus ❑ Mitral valve disease or significant cardiomyopathy or heart failure | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
IV heparin | 3 week oral anticoagulation | TEE | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Cardioversion | No LA thrombus | LA thrombus | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Sinus rhythm | Atrial fibrillation | Heparin | 3 week oral anticoagulation | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Assess stroke risk to initiate long term anticoagulation | Repeat TEE showing no LA thrombus | Repeat TEE showing LA thrombus | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Cardioversion | Initiate rate control | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atrial fibrillation | Sinus rhythm | Assess stroke risk to initiate long term anticoagulation | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Repeat cardioversion or use AV nodal blocking agents | Assess stroke risk to initiate long term anticoagulation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sinus rhythm | Atrial fibrillation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assess stroke risk to initiate long term anticoagulation | Initiate 4 week anticoagulation therapy | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Do's & Dont's
- IV amiodarone or digoxin may be considered to slow a rapid ventricular response in patients with ACS and AF associated with severe LV dysfunction and HF.
- Avoid beta blockers to control the ventricular rate in patients with AF and chronic obstructive pulmonary disease.
- Avoid amiodarone, adenosine, digoxin, or calcium channel antagonists (oral or intravenous) in patients with WPW syndrome who have pre-excited AF.
- In AF with HF, it is reasonable to perform AV node ablation with ventricular pacing to control heart rate when pharmacological therapy is insufficient or not tolerated.
- For patients with AF and rapid ventricular response causing or suspected of causing tachycardia induced cardiomyopathy, it is reasonable to achieve rate control by either AV nodal blockade or a rhythm-control strategy.